Augmentation with olanzapine in TCA-refractory depression with melancholic features: A consecutive case series

Human Psychopharmacology

Volumn 23, Issue 3, 2008, Pages 217-220

  Takahashi, Hitoshi ^a   Kamata, Mitsuhiro ^b   Yoshida, Keizo ^c   Higuchi, Hisashi ^d   Ishigooka, Jun ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b Yuri Kumiai General Hospital   (Japan)

^c NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Augmentation; Depression; Melancholia; Olanzapine; Tricyclic antidepressant

Indexed keywords

AMITRIPTYLINE; BENZODIAZEPINE DERIVATIVE; OLANZAPINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADD ON THERAPY; ADULT; ARTICLE; BLURRED VISION; CASE STUDY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONSTIPATION; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HOSPITAL PATIENT; HUMAN; MAJOR DEPRESSION; MALE; MELANCHOLIA; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OPEN STUDY; PRIORITY JOURNAL; SEDATION; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; XEROSTOMIA;

ADULT; AMITRIPTYLINE; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DEPRESSIVE DISORDER; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INPATIENTS; MALE; MIDDLE AGED;

EID: 42549107413     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.914     Document Type: Article

References (15)

1. Almeras N, Despres JP, Villeneuve J, et al. 2004. Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics. J Clin Psychiatry 65: 557-564.
2. Amsterdam JD. 1998. Selective serotonin reuptake inhibitor efficacy in severe and melancholic depression. J Psychopharmacol 12 (Suppl. B): 99-111.
3. Anderson IM. 1998. SSRIs versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety 7 (Suppl. 1): 11-17.
4. Anderson IM. 2000. Selective serotonin reuptake inhibitors versus tricyclicantidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 58: 19-36.
5. Chouinard G, Margolese HC. 2005. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res 76: 247-265.
6. Joffe RT, Singer W, Levitt AJ, MacDonald C. 1993. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 50: 387-393.
7. Li XM, Perry KW, Wong DT, Bymaster FP. 1998. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology (Berl) 136: 153-161.
8. Marek GJ, Carpenter LL, McDougle CJ, Price LH. 2003. Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmacology 28: 402-412.
9. Montes JM, Ferrando L, Saiz-Ruiz J. 2004. Remission in major depression with two antidepressant mechanisms: results from a naturalistic study. J Affect Disord 79: 229-234.
10. Montgomery SA, Asberg M. 1979. A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382-389.
11. Nemeroff CB. 2005. Use of atypical antipsychotics in refractory depression and anxiety. J Clin Psychiatry 66: 13-21.
12. Schopf J, Baumann P, Lemarchand T, Rey M. 1989. Treatment of endogenous depressions resistant to tricyclic antidepressants or related drugs by lithium addition. Results of a placebo-controlled double-blind study. Pharmacopsychiatry 22: 183-187.
13. Sharpley AL, Attenburrow ME, Hafizi S, Cowen PJ. 2005. Olanzapine increases slow wave sleep and sleep continuity in SSRI-resistant depressed patients. J Clin Psychiatry 66: 450-454.
14. Stage KB, Bech P, Grato LF, Kragh-Sorensen P, Rosenberg C, Ohrberg S. 1998. Are in-patient depressives more often of the melancholic subtype? Acta Psychiatr Scand 98: 432-436.
15. Zimmerman M, Chelminski I, Posternak M. 2004. A review of studies of the Montgomery-Asberg Depression Rating Scale in controls: implications for the definition of remission in treatment studies of depression, Int Clin Psychopharmacol 19: 1-7.